Medasense Biometrics Ltd
16
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
18.8%
3 terminated/withdrawn out of 16 trials
80.0%
-6.5% vs industry average
6%
1 trials in Phase 3/4
0%
0 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Impact of NOL Intraoperative Guided Fentanyl Analgesia vs SCC for Elective Major Abdominal Surgery
Role: lead
Nociception-Level (NOL) for the Assessment of Pain in Patient Unable to Self-Report
Role: lead
Impact of Nociceptive-Level (NOL) Intraoperative Guided Analgesia During Gynecological Laparoscopic Surgery Under General Anesthesia
Role: collaborator
Performance Assessment of the PMD-200 in Subjects at Neurointensive Care Unit
Role: lead
Performance Assessment Of The PMD-200 In Subjects With Degenerative Lumbar Spine Disease Who Requires Surgical Procedure
Role: lead
Postoperative Benefits of Intraoperative Nociception Level (NOL) Titration - Pilot
Role: lead
Performance Assessment of the PMD-200 in Subjects Requiring Surgery Under General Anesthesia
Role: lead
Evaluation of Medasense's PMD-200 During Surgery and Post Anesthesia Care
Role: lead
Monitoring Changes in Physiological Parameters by Utilization of the Combined Physiological Activity Index (CPAI)
Role: lead
Clinical Validation of Medasense Pain Response Index (PRI)
Role: lead
NoL and BIS Monitoring on Patients Recovery and Safety After Surgery
Role: collaborator
Observational Evaluation of the Last Version of the PMD200TM
Role: collaborator
Evaluation of NoL Index and ANI After Nociceptive Stimulation at Different Infusion Rates of Remifentanil Infusion
Role: collaborator
The Medasense Study
Role: collaborator
Clinical Evaluation of Medasense Pain Monitor Performances
Role: lead
Pain Monitoring Using Plurality of Non-invasive Physiological Measurement
Role: lead
All 16 trials loaded